Overview
Swedish probiotic firm's Q4 net sales rose 32% organically
Operating profit for Q4 increased by 17%, maintaining a 27% operating margin
Pediatrics segment Q4 sales rose 34% organically, Adult Health up 27%
Outlook
BioGaia did not provide specific financial guidance for future quarters or the full year
Result Drivers
PEDIATRICS GROWTH - Q4 sales in Pediatrics segment rose 34% organically, driven by demand for Protectis drops and Prodentis for children
ADULT HEALTH GROWTH - Adult Health segment Q4 sales increased 27% organically, with strong performance from Gastrus Pure Action capsules
REGIONAL EXPANSION - Direct distribution and regional growth in USA and APAC contributed to Q4 sales increase
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
SEK 0.98
Q4 Net Income
SEK 98.80 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Biogaia AB is SEK135.00, about 28.3% above its February 11 closing price of SEK105.20
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 26 three months ago
Press Release: ID:nWkr3LRN1v
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
